Skip to main content
    E

    Evogene (EVGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    +0.02 (+5.58%)

    Market Cap: $6.70M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Evogene (EVGN) Financials: Revenue, Profit and Cash Flow

    Updated Aug 18, 2026. Financial statements from company filings, amounts in US dollars.

    Evogene reported revenue of $3.85M for the fiscal year ended Dec 31, 2025, down 30.9% from the year before. That year, net income was -$8.48M with a net margin of -220.2%, operating cash flow was -$13.50M and free cash flow was -$13.64M. The quarter ended Jun 30, 2026 had revenue of $347.00K and net income of -$1.77M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $6.54M, a compound annual decline of 5.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.85M-30.9%-6.3%-364.2%-220.2%
    Dec 2024$5.58M+87.0%57.3%-337.2%-295.6%
    Dec 2023$2.98M+78.0%50.0%-745.5%-800.8%
    Dec 2022$1.68M+80.1%45.7%-1608.4%-1590.3%
    Dec 2021$930.00K-10.6%17.5%-3328.3%-2988.5%
    Dec 2020$1.04M+38.1%44.8%-2386.0%-2247.5%
    Dec 2019$753.00K-56.9%55.6%-2810.9%-2405.3%
    Dec 2018$1.75M-48.3%16.9%-1144.2%-1188.2%
    Dec 2017$3.38M-48.3%15.9%-649.1%-616.3%
    Dec 2016$6.54MN/A13.8%-322.5%-299.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.85M$5.58M$2.98M$1.68M$930.00K$1.04M$753.00K$1.75M$3.38M$6.54M
    Cost of revenue$4.09M$2.38M$1.49M$909.00K$767.00K$574.00K$334.00K$1.45M$2.85M$5.64M
    Gross profit-$241.00K$3.20M$1.49M$766.00K$163.00K$466.00K$419.00K$295.00K$536.00K$901.00K
    Research and development$7.99M$12.51M$16.20M$20.79M$21.13M$17.29M$15.79M$14.69M$16.99M$16.41M
    Operating income-$14.03M-$18.80M-$22.23M-$26.94M-$30.95M-$24.81M-$21.17M-$19.99M-$21.95M-$21.09M
    Net income-$8.48M-$16.48M-$23.88M-$26.64M-$27.79M-$23.37M-$18.11M-$20.76M-$20.84M-$19.59M
    EBITDA-$12.20M-$13.36M-$20.53MN/A-$27.88M-$23.21M-$16.02M-$18.76M-$18.68M-$18.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$347.00K$334.00K$314.00K$312.00K$884.00K$2.44M$1.61M$1.74M$605.00K$4.19M$578.00K$3.77M
    Gross profit-$8.00K$204.00K-$1.97M$155.00K$748.00K$830.00K$856.00K$698.00K$269.00K$3.88M$180.00K$3.26M
    Operating income-$2.44M-$3.15M-$5.21M-$2.72M-$3.07M-$4.13M-$4.57M-$5.92M-$4.63M-$4.09M-$7.63M-$4.18M
    Net income-$1.77M-$5.87M-$5.31M$3.87M-$4.46M-$2.59M$427.00K-$7.63M-$5.42M-$3.86M-$6.60M-$3.98M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $716.00K by $12.24M. Shareholder equity was negative, at -$82.00K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$20.05M$39.86M$51.10M$56.13M$76.30M$71.92M$71.36M$58.69M$77.60M$95.99M
    Current assets$15.63M$21.59M$34.47M$37.75M$56.89M$51.82M$49.03M$55.49M$72.79M$89.49M
    Cash and equivalents$12.96M$15.30M$20.77M$28.98M$32.33M$46.23M$34.75M$5.81M$3.44M$3.24M
    Total liabilities$8.07M$25.03M$22.42M$21.34M$12.88M$15.03M$11.15M$8.39M$8.22M$8.70M
    Short-term debt$716.00K$10.96M$853.00K$884.00K$974.00K$777.00K$895.00K$2.03M$2.83M$2.68M
    Long-term debtN/AN/A$10.37M$10.11MN/AN/AN/AN/AN/AN/A
    Shareholder equity-$82.00K-$1.45M$12.05M$27.93M$53.65M$46.05M$50.14M$50.05M$69.38M$87.29M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$13.44M$17.95M$20.05M$26.09M$33.93M$34.30M$39.86M$40.11M$40.97M$46.78M$51.10M$57.75M
    Total liabilities$7.67M$9.96M$8.07M$8.83M$21.55M$21.91M$25.03M$27.88M$21.03M$21.40M$22.42M$21.88M
    Cash and equivalents$9.35M$8.51M$12.96M$5.63M$8.33M$7.50M$15.30M$11.32M$9.48M$11.91M$20.77M$27.33M
    Shareholder equity-$3.29M-$2.54M-$82.00K$1.14M-$3.55M-$3.65M-$1.45M-$4.34M$3.07M$8.29M$12.05M$18.51M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$13.50M-$19.70M-$21.58M-$23.68M-$24.84M-$19.51M-$17.36M-$15.16M-$15.93M-$11.69M
    Capital expenditures$135.00K$626.00K$785.00K$1.17M$724.00K$682.00K$900.00K$374.00K$590.00K$808.00K
    Free cash flow-$13.64M-$20.33M-$22.36M-$24.85M-$25.56M-$20.20M-$18.26M-$15.54M-$16.52M-$12.50M
    Investing cash flow$17.74M$9.62M-$4.54M$13.27M-$20.44M$9.41M$37.14M$17.35M$15.24M$4.03M
    Financing cash flow-$6.60M$4.66M$18.15M$9.34M$30.28M$20.37M$9.00M$297.00K$814.00K$655.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$2.10M-$2.95M-$2.69M-$3.80M-$2.33M-$5.18M-$5.21M-$4.93M-$5.46M-$4.11M-$5.92M-$4.32M
    Capital expenditures$9.29K$2.00K$6.00K$11.37K$1.51K$122.00K$322.00K$132.00K$26.00K$141.00K$86.00K$216.00K
    Free cash flow-$2.11M-$2.96M-$2.69M-$3.81M-$2.33M-$5.30M-$5.53M-$5.06M-$5.48M-$4.25M-$6.01M-$4.53M
    Last 12 quarters

    Frequently Asked Questions About EVGN

    What is Evogene's annual revenue?

    Evogene reported revenue of $3.85M for the fiscal year ended Dec 31, 2025.

    How fast is Evogene's revenue growing?

    Revenue was down 30.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 32.0%.

    Is Evogene profitable?

    No. Evogene reported net income of -$8.48M for the fiscal year ended Dec 31, 2025, with a net margin of -220.2%.

    How much free cash flow does EVGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.50M minus capital expenditures of $135.00K produced free cash flow of -$13.64M.

    How much debt does Evogene have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $716.00K and cash and equivalents of $12.96M.